Coco Diethanolamide

Summary

Coco Diethanolamide (CHEMBL4297547) is a phase-3 clinical-stage unknown; indicated across 1 condition including lice infestation.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 1 condition
• Clinical trials: 2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297547
Name	Coco Diethanolamide
Type	Unknown
Max phase	3

Also known as: Amidex ce surfactant, Calamide c, Cocamide dea, Cocamide diethanolamine, Coco diethanolamide, Cocodiethanolamide, Coconut diethanolamide, Coconut fatty acid diethanolamide, N,n-bis(hydroxyethyl)cocamine, COCO DIETHANOLAMIDE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
lice infestation	3	MONDO:0003472	MONDO:0003472

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE2/PHASE3	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02499549	PHASE2/PHASE3	TERMINATED	Two Treatment Regimens of Cocamide DEA Lotion for Head Lice
NCT02500524	PHASE3	TERMINATED	Cocamide DEA vs Permethrin for Head Lice

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).